Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
← catalyst calendarNCT07297979 · readout in 1,375 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
50estimated
Sites
8
Countries
Australia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-08 | actual | When the study began enrolling |
| Primary completion | 2030-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Ewing Sarcoma
Intervention
- Drug: Xaluritamig — also filed as AMG 509
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants Experiencing a Dose-limiting Toxicity (DLT) (Part 1 Only)
measured Up to 42 days
Number of Participants with Treatment-emergent Adverse Events
measured Up to approximately 2.5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed